[Cases of the regression of advanced bladder tumors (T2-T4) after the use of chemotherapy].

A. Yagoda reports that modern therapeutic schemas applied for treatment of bladder tumors have essentially increased the response rate: more than 50 per cent with full response (CRs), within the range from 28 to 40 per cent persisting for a period from 11 to more than 32 months. What appears new, noted by this author, is the complete disappearance of the tumor (restaging) following chemotherapy, demonstrated surgically and on pathologic examination. Proceeding from the current trends in the treatment of bladder tumors and the use of modern chemotherapeutic schemes, the authors describe 4 cases of regression of advanced tumors. This was based on criteria of clinico-laboratory assay, which included urethroscopy with transurethral echography and biopsy specimen examination, computer axial tomography of pelvis and kidneys, radioisotopic examination of kidneys, chest X-ray. Two patients received combined treatment by a scheme with methotrexate, biocysplatinum and biocarbazine; a three-year survival without relapse was recorded. The other two patients were treated using M-VAC scheme (methotrexate, vinblastine, adriamycin and biocysplatinum). They have been under observation for 18 months and had no relapse.